Jpmorgan Chase & CO Astria Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 36,032 shares of ATXS stock, worth $299,425. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,032
Previous 54,664
34.08%
Holding current value
$299,425
Previous $481,000
60.08%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ATXS
# of Institutions
109Shares Held
49.2MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$53.9 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.52MShares$37.6 Million1.28% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$34.1 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$29.5 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$29.2 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $126M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...